EDP-1815 by Evelo Biosciences for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval

EDP-1815 is under clinical development by Evelo Biosciences and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EDP-1815’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EDP-1815 overview

EDP-1815 is under development for the treatment of rheumatoid arthritis, skin inflammation, psoriasis, atopic dermatitis, and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The therapeutic candidate is administered through oral route as a capsule. It is non-live single strain bacterial-based therapeutics that acts by down-regulating the immune system.

It was under development for the treatment of influenza viral infection and also for coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Evelo Biosciences overview

Evelo Biosciences is a biotechnology company. It develops orally delivered product candidates for the treatment of inflammatory diseases and cancer. The company is investigating pipeline product EDP1815 and EDP1867, targeting SARS-CoV-2 virus, psoriasis, atopic dermatitis, and inflammatory diseases; and EDP1908, an anti-PD-1 therapy for multiple cancers. Its proprietary Sintax, an integrated platform develops oral biologics which harness the cells in the small intestine. Evelo Biosciences is also evaluating novel therapies to treat chronic diseases and cancer. The company’s Evelo is a trademark of Evelo Biosciences. It has its operations in the US, and the UK. Evelo Biosciences is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of EDP-1815’s drug-specific PTSR and LoA scores, buy the report here.